Falcon Genomics continues to work toward its goal of seeing its research-use-only Cancer Biochip System adopted in a clinical setting.

As part of that effort, the company recently demonstrated in two papers the ability of the platform to test the effectiveness of different short-interfering RNAs targeting genes in breast cancer cells to reveal therapeutic targets. In addition, Falcon is developing a higher-throughput, next-generation version of the system, according to a company executive.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.